Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal.
Because inflammation by now is a "traditional" finding that predicts poor outcome and cardiovascular events in the vast majority of patients with ESRD, it could be argued that inflammatory biomarkers should not longer be considered "novel" risk factors. In this review, we forward the hypothesis that, in addition to putative direct proatherogenic effects, persistent inflammation may serve as a catalyst and, in the toxic uremic milieu, modulate the effects of other concurrent vascular and nutritional risk factors. We discuss some recent observational studies, suggesting that the presence of persistent inflammation magnifies the risk for poor outcome via mechanisms related to self-enhancement of the inflammatory cascade and exacerbation of both the wasting and the vascular calcification processes. Because persistent inflammation may be the silent culprit of other commonly observed pathophysiologic alterations in chronic kidney disease, it is imperative that inflammatory markers be regularly monitored and therapeutic attempts be made to target persistent low-grade inflammation in this patient group.
Carrero
Juan Jesús
JJ
Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden.
Stenvinkel
Peter
P
D015415:Biomarkers / Q000097:blood; D002114:Calcinosis / Q000276:immunology; D016207:Cytokines / Q000097:blood; D018450:Disease Progression; D006801:Humans; D007249:Inflammation / Q000276:immunology* / Q000628:therapy; D018836:Inflammation Mediators / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D011502:Protein-Energy Malnutrition / Q000276:immunology; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000276:immunology
D015415:Biomarkers; D016207:Cytokines; D018836:Inflammation Mediators